Hyperphosphorylated Tau is Elevated in Alzheimer's Disease with Psychosis
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Psychosis occurs in 40-60% of Alzheimer's disease (AD) subjects, is heritable, and indicates a more rapidly progressive disease phenotype. Neuroimaging and postmortem evidence support an exaggerated prefrontal cortical synaptic deficit in AD with psychosis. Microtubule-associated protein tau is a key mediator of amyloid-β-induced synaptotoxicity in AD, and differential mechanisms of progressive intraneuronal phospho-tau accumulation and interneuronal spread of tau aggregates have recently been described. We hypothesized that psychosis in AD would be associated with greater intraneuronal concentration of phospho-tau and greater spread of tau aggregates in prefrontal cortex. We therefore evaluated prefrontal cortex phospho-tau in a cohort of 45 AD cases with and without psychosis. Intraneuronal phospho-tau concentration was higher in subjects with psychosis, while a measure of phospho-tau spread, volume fraction, was not. Across groups both measures were associated with lower scores on the Mini-Mental State Examination and Digit Span Backwards test. These novel findings indicate that tau phosphorylation may be accelerated in AD with psychosis, indicating a more dynamic, exaggerated pathology in AD with psychosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172 · cited 1×
“The presence of these immunoreactive threads in the DLPFC, which are likely non-argyrophilic pTau [57], demonstrate pTau is spreading regionally even early in disease progression.”
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
Montine, T. J., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., Mirra, S. S., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0910-3 · Cited by 2,894 · cited 1×
“Although neuropathologic diagnostic criteria emphasize combining these two stages [59, 60], for more subtle clinical pathologic correlations they are probably best analyzed separately.”
Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity
DeKosky, S. T., & Scheff, S. W. (1990) · Annals of Neurology · doi:10.1002/ana.410270502 · Cited by 2,376
Aβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892 · cited 2×
“However, while it is appreciated that Aβ drives missorting and phosphorylation of tau [50] and that reducing tau mitigates effects of Aβ [29], it is unclear how the ratio of Aβ isoforms may influence tau pathology.”
HYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
Propagation of Tau Pathology in a Model of Early Alzheimer's Disease
de Calignon, A., Polydoro, M., Suárez-Calvet, M., William, C., Adamowicz, D. H., Kopeikina, K. J., Pitstick, R., Sahara, N., Ashe, K. H., Carlson, G. A., et al. (2012) · Neuron · doi:10.1016/j.neuron.2011.11.033 · Cited by 1,427
Augustinack, J. C., Schneider, A., Mandelkow, E.-M., & Hyman, B. T. (2002) · Acta Neuropathologica · doi:10.1007/s004010100423 · Cited by 998 · cited 1×
“Tau is also phosphorylated in AD in a progressive manner, with different phosphorylation sites corresponding to different degrees of cytopathology, from intraneuronal tau inclusions to ghost tangles [31].”
Koffie, R. M., Meyer-Luehmann, M., Hashimoto, T., Adams, K. W., Mielke, M. L., Garcia-Alloza, M., Micheva, K. D., Smith, S. J., Kim, M. L., Lee, V. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811698106 · Cited by 850
Evolution of the neuropathology of Alzheimer's disease
Braak, H., & Braak, E. (1996) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1996.tb05866.x · Cited by 710 · cited 1×
“Additionally, as time progresses and tau deposits transition to late extracellular ghost tangles, AT8 immunoreactivity diminishes [67–70], potentially affecting our measure of MI.”
Zempel, H., Thies, E., Mandelkow, E., & Mandelkow, E.-M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2357-10.2010 · Cited by 686 · cited 2×
“However, while it is appreciated that A drives missorting and phosphorylation of tau [50] and that reducing tau mitigates effects of A [29], it is unclear how the ratio of A isoforms may influence tau pathology.”
Neuropathology and Cognitive Impairment in Alzheimer Disease: A Complex but Coherent Relationship
Nelson, P. T., Braak, H., & Markesbery, W. R. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181919a48 · Cited by 643 · cited 2×
“This is consistent with other data indicating substantial differences in degree of cognitive impairments between individuals at Braak stage V and VI [58].”
Monoclonal antibody AT8 recognises tau protein phosphorylated at both serine 202 and threonine 205
Goedert, M., Jakes, R., & Vanmechelen, E. (1995) · Neuroscience Letters · doi:10.1016/0304-3940(95)11484-e · Cited by 608
Schneider, A., Biernat, J., von Bergen, M., Mandelkow, E., & Mandelkow, E.-M. (1999) · Biochemistry · doi:10.1021/bi981874p · Cited by 564
Kuperstein, I., Broersen, K., Benilova, I., Rozenski, J., Jonckheere, W., Debulpaep, M., Vandersteen, A., Segers‐Nolten, I., Van Der Werf, K., Subramaniam, V., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.211 · Cited by 532
Neuropsychiatric symptoms in Alzheimer's disease: Past progress and anticipation of the future
Geda, Y. E., Schneider, L. S., Gitlin, L. N., Miller, D. S., Smith, G. S., Bell, J., Evans, J., Lee, M., Porsteinsson, A., Lanctôt, K. L., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.12.001 · Cited by 378 · cited 1×
“Evidence is accumulating that cortical synapses in AD+P are more vulnerable to the pathological factors of AD, which contributes to the development of psychotic symptoms, or at least more pronounced cognitive impairments [10, 11].”
Self-citationNeuroanatomical correlates of neuropsychiatric symptoms in Alzheimer's disease
Bruen, P. D., McGeown, W. J., Shanks, M. F., & Venneri, A. (2008) · Brain · doi:10.1093/brain/awn151 · Cited by 374
Tau Protein Is Required for Amyloid β-Induced Impairment of Hippocampal Long-Term Potentiation
Shipton, O. A., Leitz, J. R., Dworzak, J., Acton, C. E. J., Tunbridge, E. M., Denk, F., Dawson, H. N., Vitek, M. P., Wade-Martins, R., Paulsen, O., et al. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.2610-10.2011 · Cited by 315 · cited 1×
“Tau may also be essential to the cascade of synaptic pathology induced by soluble Aβ, as tau knockout transgenic models fail to show Aβ-induced neurite degeneration [27], Aβ-induced impairment of long-term potentiation [28], or Aβ-induced cognitive deficits [29].”
Nelson, P. T., Jicha, G. A., Schmitt, F. A., Liu, H., Davis, D. G., Mendiondo, M. S., Abner, E. L., & Markesbery, W. R. (2007) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/nen.0b013e31815c5efb · Cited by 292 · cited 1×
“by discrete NFT counts [61] and by Braak stage strati-”
Alzheimer’s disease-related alterations in synaptic density: neocortex and hippocampus.
Scheff, S. W., & Price, D. A. (2006) · Journal of Alzheimer's Disease · doi:10.3233/jad-2006-9s312 · Cited by 284
Incidence of and risk factors for hallucinations and delusions in patients with probable AD
Paulsen, J. S., Salmon, D. P., Thal, L. J., Romero, R., Weisstein–Jenkins, C., Galasko, D., Hofstetter, C. R., Thomas, R., Grant, I., & Jeste, D. V. (2000) · Neurology · doi:10.1212/wnl.54.10.1965 · Cited by 254
Cerebral correlates of psychotic symptoms in Alzheimer's disease
Mega, M. S. (2000) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.69.2.167 · Cited by 189 · cited 1×
“studies comparing AD+P to AD without psychosis dorsolateral prefrontal cortex (DLPFC), and parietal regions in AD+P [15–17].”
Determination of absolute protein numbers in single synapses by a GFP-based calibration technique
Sugiyama, Y., Kawabata, I., Sobue, K., & Okabe, S. (2005) · Nature Methods · doi:10.1038/nmeth783 · Cited by 189 · cited 1×
“While a direct, linear relationship specifically between MI and pTau concentration has not been firmly established, we have previously shown that detected fluorescence intensity is directly related to the intensity of fluorescent microspheres embedded in thick sections [47], and can be used to accurately measure prote…”
Kalirin regulates cortical spine morphogenesis and disease-related behavioral phenotypes
Cahill, M. E., Xie, Z., Day, M., Photowala, H., Barbolina, M. V., Miller, C. A., Weiss, C., Radulovic, J., Sweatt, J. D., Disterhoft, J. F., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904636106 · Cited by 170 · cited 1×
“Recently we determined that kalirin, a protein essential for cortical dendritic spine maintenance and growth [23], is reduced in AD+P DLPFC [22].”
Wang, J.-W., Imai, Y., & Lu, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.5094-06.2007 · Cited by 80 · cited 1×
“phosphorylation in an LKB1-dependent manner [53].”
Cited by
Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms
Lanctôt, K. L., Amatniek, J., Ancoli‐Israel, S., Arnold, S. E., Ballard, C., Cohen‐Mansfield, J., Ismail, Z., Lyketsos, C., Miller, D. S., Musiek, E., et al. (2017) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2017.07.001 · Cited by 395
“[47] Murray PS, Kirkwood CM, Gray MC, Fish KN, Ikonomovic MD, Hamilton RL, et al.”
BackgroundPsychosis in Alzheimer disease—mechanisms, genetics and therapeutic opportunities
Ismail, Z., Creese, B., Aarsland, D., Kales, H. C., Lyketsos, C. G., Sweet, R. A., & Ballard, C. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-021-00597-3 · Cited by 189
Self-citationNeurotheranostics as Personalized Medicines
Kevadiya, B. D., Ottemann, B. M., Thomas, M. B., Mukadam, I., Nigam, S., McMillan, J., Gorantla, S., Bronich, T. K., Edagwa, B., & Gendelman, H. E. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.10.011 · Cited by 124
Behavioral and neuropsychiatric disorders in Alzheimer's disease
Cortés, N., Andrade, V., & Maccioni, R. B. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180005 · Cited by 57
“In addition, there is an increase in SP, NFT, and higherlevelsofphosphorylatedtau,alsobeingassoci-atedwithdiminutioninserotonergicsystem[61,62].”
Koppel, J., Jimenez, H., Adrien, L., H. Chang, E., Malhotra, A. K., & Davies, P. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14593 · Cited by 22
Metadata
- Authors
- Murray, P. S., Kirkwood, C. M., Gray, M. C., Fish, K. N., Ikonomovic, M. D., Hamilton, R. L., Kofler, J. K., Klunk, W. E., Lopez, O. L., & Sweet, R. A.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2014-02-14
- Volume
- 39
- Issue
- 4
- Pages
- 759-773
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1487348428
- Cited by
- 65
- References
- 27
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.